{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:25:23Z","timestamp":1787066723765,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["CTN-103"],"award-info":[{"award-number":["CTN-103"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorder (MOUD; methadone, buprenorphine, and naltrexone) have demonstrated effectiveness in reducing opioid overdose and mortality. Methadone access barriers disproportionally impact rural areas and naltrexone uptake has been limited. Buprenorphine availability has increased and relaxed regulations reduces barriers in general medical settings common in rural areas.\u00a0Barriers to prescribing buprenorphine include lack of confidence, inadequate training, and lack of access to experts. To address these barriers, learning collaboratives have trained clinics on best-practice performance data collection to inform quality improvement (QI). This project sought to explore the feasibility of training clinics to collect performance data and initiate QI alongside clinics\u2019 participation in a Project ECHO virtual collaborative for buprenorphine providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighteen New Hampshire clinics participating in a Project ECHO were offered a supplemental project exploring the feasibility of performance data collection to inform QI targeting increased alignment with best practice. Feasibility was assessed descriptively, through each clinic\u2019s participation in training sessions, data collection, and QI initiatives. An end-of-project survey was conducted to understand clinic staff perceptions of how useful and acceptable they found the program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five of the eighteen health care clinics that participated in the Project ECHO joined the training project, four of which served rural communities in New Hampshire. All five clinics met the criteria for engagement, as each clinic attended at least one training session, submitted at least one month of performance data, and completed at least one QI initiative. Survey results showed that while clinic staff perceived the training and data collection to be useful, there were several barriers to collecting the data, including lack of staff time, and difficulty standardizing documentation within the clinic electronic health record.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results suggest that training clinics to monitor their performance and base QI initiatives on data has potential to impact clinical best practice. While data collection was inconsistent, clinics completed several data-informed QI initiatives, indicating that smaller scale data collection might be more attainable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-023-00381-2","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T23:58:40Z","timestamp":1682639920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Augmenting project ECHO for opioid use disorder with data-informed quality improvement"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-9763","authenticated-orcid":false,"given":"Owen B.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany M.","family":"McLeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Marsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delitha","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Ryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"381_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). Opioid Overdose, Opioid Basics, Understanding the Epidemic. Accessed May 12, 2021.; Available from: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html."},{"key":"381_CR2","unstructured":"Centers for Disease Control and Prevention (CDC). U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020\u2014But Are Still Up 15%. 2022 [cited 2022 05\/25\/2022]; Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm."},{"key":"381_CR3","unstructured":"Iowa State University. Urban Percentage of the Population for States, Historical. 2021 May 12, 2021; Available from: https:\/\/www.icip.iastate.edu\/tables\/population\/urban-pct-states."},{"key":"381_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107893","volume":"209","author":"A Meier","year":"2020","unstructured":"Meier A, et al. Understanding the increase in opioid overdoses in New Hampshire: a rapid epidemiologic assessment. Drug Alcohol Depend. 2020;209: 107893.","journal-title":"Drug Alcohol Depend"},{"key":"381_CR5","unstructured":"Kaiser Family Foundation. Opioid Overdose Death Rates and All Drug Overdose Death Rates per 100,000 Population (Age-Adjusted). State Health Facts 2022 June 8, 2022]; Available from: https:\/\/www.kff.org\/other\/state-indicator\/opioid-overdose-death-rates\/?currentTimeframe=6&sortModel=%7B%22colId%22:%22Opioid%20Overdose%20Death%20Rate%20(Age-Adjusted)%22,%22sort%22:%22desc%22%7D."},{"issue":"10182","key":"381_CR6","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","volume":"393","author":"C Blanco","year":"2019","unstructured":"Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760\u201372.","journal-title":"Lancet"},{"issue":"2","key":"381_CR7","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622\u2013e1920622.","journal-title":"JAMA Netw Open"},{"key":"381_CR8","unstructured":"National Academies of Sciences, Engineering, and Medicine (NASEM). In: Leshner AI, Mancher M. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press; 2019. p. 174."},{"key":"381_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106541","volume":"152","author":"RA Jenkins","year":"2021","unstructured":"Jenkins RA. The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective. Prev Med. 2021;152: 106541.","journal-title":"Prev Med"},{"issue":"1","key":"381_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.1735","volume":"13","author":"RA Rosenblatt","year":"2015","unstructured":"Rosenblatt RA, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Annal Fam Med. 2015;13(1):23\u20136.","journal-title":"Annal Fam Med"},{"issue":"7","key":"381_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.7326\/M19-2403","volume":"172","author":"RK McBain","year":"2020","unstructured":"McBain RK, et al. Growth and distribution of buprenorphine-waivered providers in the United States, 2007\u20132017. Ann Intern Med. 2020;172(7):504\u20136.","journal-title":"Ann Intern Med"},{"key":"381_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107968","volume":"211","author":"PJ Joudrey","year":"2020","unstructured":"Joudrey PJ, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alcohol Depend. 2020;211: 107968.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"381_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","volume":"77","author":"RA Kleinman","year":"2020","unstructured":"Kleinman RA. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiat. 2020;77(11):1163\u201371.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"381_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/ajad.12786","volume":"27","author":"G Chang","year":"2018","unstructured":"Chang G, et al. Adherence to extended release naltrexone: patient and treatment characteristics. Am J Addict. 2018;27(6):524\u201330.","journal-title":"Am J Addict"},{"key":"381_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"381_CR16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/add.14733","volume":"114","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Rosenheck RA. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Addiction. 2019;114(11):1992\u20139.","journal-title":"Addiction"},{"issue":"1","key":"381_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1377\/hlthaff.2018.05145","volume":"38","author":"H Wen","year":"2019","unstructured":"Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff. 2019;38(1):24\u20138.","journal-title":"Health Aff"},{"issue":"6","key":"381_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"39","author":"M Olfson","year":"2020","unstructured":"Olfson M, et al. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists. And Others Health Affairs. 2020;39(6):984\u201392.","journal-title":"And Others Health Affairs"},{"issue":"11","key":"381_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","volume":"316","author":"BD Stein","year":"2016","unstructured":"Stein BD, et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211\u20132.","journal-title":"JAMA"},{"issue":"2","key":"381_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1077558718793070","volume":"77","author":"CHA Andrilla","year":"2020","unstructured":"Andrilla CHA, et al. Projected contributions of nurse practitioners and physicians assistant to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2020;77(2):208\u201316.","journal-title":"Med Care Res Rev"},{"issue":"12","key":"381_CR21","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1377\/hlthaff.2019.00859","volume":"38","author":"ML Barnett","year":"2019","unstructured":"Barnett ML, Lee D, Frank RG. In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Aff. 2019;38(12):2048\u201356.","journal-title":"Health Aff"},{"key":"381_CR22","unstructured":"US Department of Health and Human Services, Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. 2021: National Archives Federal Register, p. 86 FR 22439\u201322440."},{"issue":"1","key":"381_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M18-3457","volume":"171","author":"T Beetham","year":"2019","unstructured":"Beetham T, et al. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1\u20139.","journal-title":"Ann Intern Med"},{"key":"381_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1\u20137.","journal-title":"J Subst Abuse Treat"},{"key":"381_CR25","unstructured":"Dr. Gupta Applauds Removal of X-Waiver in Omnibus, Urges Healthcare Providers to Treat Addiction. December 30, 2022, The White House: ONDCP Briefing Room, https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2022\/12\/30\/dr-gupta-applauds-removal-of-x-waiver-in-omnibus-urges-healthcare-providers-to-treat-addiction\/."},{"key":"381_CR26","unstructured":"PEW Trusts. President Signs Bipartisan Measure to Improve Addiction Treatment. 2022 [cited 2023 January 11, 2023]; Available from: https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/articles\/2022\/12\/30\/president-signs-bipartisan-measure-to-improve-addiction-treatment."},{"issue":"3","key":"381_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/add.14436","volume":"114","author":"CM Jones","year":"2019","unstructured":"Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471\u201382.","journal-title":"Addiction"},{"issue":"2","key":"381_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jrh.12404","volume":"36","author":"CHA Andrilla","year":"2020","unstructured":"Andrilla CHA, Jones KC, Patterson DG. Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine. J Rural Health. 2020;36(2):187\u201395.","journal-title":"J Rural Health"},{"key":"381_CR29","first-page":"3019","volume":"15","author":"J DeFlavio","year":"2015","unstructured":"DeFlavio J, Nordstrom RS, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.","journal-title":"Rural Remote Health"},{"issue":"2_Suppl","key":"381_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/00333549071220S214","volume":"122","author":"S Arora","year":"2007","unstructured":"Arora S, et al. Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep. 2007;122(2_Suppl):74\u20137.","journal-title":"Public Health Rep"},{"issue":"1","key":"381_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","volume":"37","author":"M Komaromy","year":"2016","unstructured":"Komaromy M, et al. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20\u20134.","journal-title":"Subst Abus"},{"key":"381_CR32","doi-asserted-by":"crossref","unstructured":"Shea CM, Gertner AK, Green SL. Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: a qualitative study. Subst Abus. 2019; 1\u201311.","DOI":"10.1080\/08897077.2019.1694617"},{"issue":"1","key":"381_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-021-00215-z","volume":"16","author":"HM Puckett","year":"2021","unstructured":"Puckett HM, Bossaller JS, Sheets LR. The impact of project ECHO on physician preparedness to treat opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):6.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"381_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40501-020-00199-8","volume":"7","author":"CM Holmes","year":"2020","unstructured":"Holmes CM, et al. Project ECHO and opioid education: a systematic review. Curr Treat Options Psychiatry. 2020;7(1):9\u201322.","journal-title":"Curr Treat Options Psychiatry"},{"issue":"1","key":"381_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12913-019-4472-8","volume":"19","author":"L Beamish","year":"2019","unstructured":"Beamish L, et al. Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting. BMC Health Serv Res. 2019;19(1):663.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"381_CR36","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/add.12117","volume":"108","author":"DH Gustafson","year":"2013","unstructured":"Gustafson DH, et al. Which elements of improvement collaboratives are most effective? A cluster-randomized trial. Addiction. 2013;108(6):1145\u201357.","journal-title":"Addiction"},{"key":"381_CR37","unstructured":"Rawson R. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorders: An Evaluation. 2017, Vermont Department of Health."},{"issue":"4","key":"381_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","volume":"11","author":"JR Brooklyn","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11(4):286\u201392.","journal-title":"J Addict Med"},{"key":"381_CR39","unstructured":"State of Vermont Blueprint for Health. Hub and Spoke. June 8, 2022]; Available from: https:\/\/blueprintforhealth.vermont.gov\/about-blueprint\/hub-and-spoke."},{"issue":"2","key":"381_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/ADM.0000000000000200","volume":"10","author":"BR Nordstrom","year":"2016","unstructured":"Nordstrom BR, et al. Using a learning collaborative strategy with office-based practices to increase access and improve quality of care for patients with opioid use disorders. J Addict Med. 2016;10(2):117\u201323.","journal-title":"J Addict Med"},{"issue":"6","key":"381_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0025-6196(11)61194-4","volume":"82","author":"P Varkey","year":"2007","unstructured":"Varkey P, Reller MK, Resar RK. Basics of quality improvement in health care. Mayo Clin Proc. 2007;82(6):735\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"381_CR42","first-page":"100559","volume":"9","author":"R Sokol","year":"2021","unstructured":"Sokol R, et al. A novel transition: lessons learned during rapid implementation and evolution of telehealth group based opioid treatment (t-GBOT) during the COVID-19 pandemic. Healthcare (Amsterdam, Netherlands). 2021;9(3):100559\u2013100559.","journal-title":"Healthcare (Amsterdam, Netherlands)"},{"issue":"6","key":"381_CR43","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/pds.4984","volume":"29","author":"AR Pashmineh Azar","year":"2020","unstructured":"Pashmineh Azar AR, et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol Drug Saf. 2020;29(6):708\u201315.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"381_CR44","unstructured":"Wickham S. The Doorway is open in NH, and hundreds are walking in. Union Leader, 2019."},{"key":"381_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103259","volume":"95","author":"SK Moore","year":"2021","unstructured":"Moore SK, et al. Implementation of a New Hampshire community-initiated response to the opioid crisis: a mixed-methods process evaluation of Safe Station. Int J Drug Policy. 2021;95: 103259.","journal-title":"Int J Drug Policy"},{"key":"381_CR46","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), TIP 63: Medications for Opioid Use Disorder, S.A.a.M.H.S. Administration, Editor. 2019."},{"key":"381_CR47","unstructured":"Department of Health and Human Services Bureau of Drug and Alcohol Services (BDAS), Guidance Document on Best Practices: Key Components for Delivering Community-Based Medication Assisted Treatment Services for Opioid Use Disorders in New Hampshire, B.o.D.a.A. Services, Editor. 2018."},{"key":"381_CR48","unstructured":"American Society of Addiction Medicine, Consensus Statement on Appropriate Use of Drug Testing in Clinical Addiction Medicine in Considerations for Office-Based Opioid Treatment Settings 2017, American Society of Addiction Medicine."},{"issue":"2","key":"381_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0951484818770411","volume":"31","author":"G Antonacci","year":"2018","unstructured":"Antonacci G, et al. The use of process mapping in healthcare quality improvement projects. Health Serv Manage Res. 2018;31(2):74\u201384.","journal-title":"Health Serv Manage Res"},{"key":"381_CR50","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain, C.f.D.C.a.P. (CDC), Editor. 2016: United States.","DOI":"10.1001\/jama.2016.1464"},{"issue":"1","key":"381_CR51","first-page":"11","volume":"46","author":"DT Liss","year":"2020","unstructured":"Liss DT, et al. Using electronic health records to measure quality improvement efforts: findings from a large practice facilitation initiative. Jt Comm J Qual Patient Saf. 2020;46(1):11\u20137.","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"4","key":"381_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1377\/hlthaff.2017.1254","volume":"37","author":"DJ Cohen","year":"2018","unstructured":"Cohen DJ, et al. Primary care practices\u2019 abilities and challenges in using electronic health record data for quality improvement. Health Aff (Millwood). 2018;37(4):635\u201343.","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"381_CR53","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3122\/jabfm.2018.03.170274","volume":"31","author":"JR Hemler","year":"2018","unstructured":"Hemler JR, et al. Practice facilitator strategies for addressing electronic health record data challenges for quality improvement: EvidenceNOW. J Am Board Fam Med. 2018;31(3):398\u2013409.","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"381_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1377\/hlthaff.2017.1254","volume":"37","author":"DJ Cohen","year":"2018","unstructured":"Cohen DJ, et al. Primary care practices\u2019 abilities and challenges in using electronic health record data for quality improvement. Health Aff. 2018;37(4):635\u201343.","journal-title":"Health Aff"},{"issue":"1","key":"381_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12875-015-0298-6","volume":"16","author":"J Kotecha","year":"2015","unstructured":"Kotecha J, et al. The role of the practice facilitators in Ontario primary healthcare quality improvement. BMC Fam Pract. 2015;16(1):93.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"381_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13012-021-01100-8","volume":"16","author":"TL Walunas","year":"2021","unstructured":"Walunas TL, et al. Does coaching matter? Examining the impact of specific practice facilitation strategies on implementation of quality improvement interventions in the Healthy Hearts in the Heartland study. Implement Sci. 2021;16(1):33.","journal-title":"Implement Sci"},{"issue":"Suppl 1","key":"381_CR57","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1370\/afm.2197","volume":"16","author":"M McHugh","year":"2018","unstructured":"McHugh M, et al. Practice facilitators\u2019 and leaders\u2019 perspectives on a facilitated quality improvement program. Annal Fam Med. 2018;16(Suppl 1):S65\u201371.","journal-title":"Annal Fam Med"},{"issue":"13","key":"381_CR58","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.3390\/ijerph17134707","volume":"17","author":"KP Wiseman","year":"2020","unstructured":"Wiseman KP, et al. An evaluation of the process and quality improvement measures of the university of virginia cancer center tobacco treatment program. Int J Environ Res Public Health. 2020;17(13):4707.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"381_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13142-016-0446-0","volume":"7","author":"JM Schindler-Ruwisch","year":"2016","unstructured":"Schindler-Ruwisch JM, et al. A content analysis of electronic health record (EHR) functionality to support tobacco treatment. Transl Behav Med. 2016;7(2):148\u201356.","journal-title":"Transl Behav Med"},{"key":"381_CR60","unstructured":"Executive Office of the President, Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. March 13, 2020, Presidential Document 85 FR 15337, 2020-05794. p. 15337\u201315338."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00381-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:22:58Z","timestamp":1682641378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00381-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00381-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ECHO-AMPLIFI quality improvement training project was approved by the Institutional Review Board for the Protection of Human Subjects in Research of the University of New Hampshire as a supplement to the PACT-MAT Project ECHO protocol. The project was not deemed human subjects research. No protected health information was gathered.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}